Treatment with a CO-releasing molecule (CORM-3) reduces joint inflammation and erosion in murine collagen-induced arthritis

Annals of the Rheumatic Diseases

Volumn 67, Issue 9, 2008, Pages 1211-1217

  Ferrandiz M L ^a   Maicas, N ^a   Garcia Arnandis, I ^a   Terencio, M C ^a   Motterlini, R ^b   Devesa, I ^c   Joosten, L A B ^c   Van Den Berg, W B ^c   Alcaraz, M J ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b NORTHWICK PARK INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; CARBON MONOXIDE RELEASING MOLECULE 3; CARTILAGE OLIGOMERIC MATRIX PROTEIN; COLLAGEN TYPE 2; CYCLOOXYGENASE 2; HEME OXYGENASE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LOCALIZATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; CYCLOOXYGENASE 2; CYTOKINES; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HEME OXYGENASE-1; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; MICE; MICE, INBRED DBA; ORGANOMETALLIC COMPOUNDS; RANK LIGAND;

EID: 50249111616     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.082412     Document Type: Article

References (31)

1. Minisini MP, Kantengwa S, Polla BS. DNA damage and stress protein synthesis induced by oxidative stress proceed independently in the human premonocytic line U937. Mutat Res 1994;315:169-79.
2. Pae HO, Choi BM, Oh GS, Lee MS, Ryu DG, Rhew HY, et al. Roles of heme oxygenase-1 in the antiproliferative and antiapoptotic effects of nitric oxide on Jurkat T cells. Mol Pharmacol 2004;66:122-8.
3. Poss KD, Tonegawa S. Heme oxygenase 1 is reguired for mammalian iron reutilization. Proc Natl Acad Sci USA 1997;94:10919-24.
4. Willis D, Moore AR, Willoughby DA. Heme oxygenase isoform expression in cellular and antibody-mediated models of acute inflammation in the rat. J Pathol 2000;190:627-34.
5. Vicente AM, Guillen MI, Habib A, Alcaraz MJ. Beneficial effects of heme oxygenase-1 up-regulation in the development of experimental inflammation induced by zymosan. J Pharmacol Exp Ther 2003;307:1030-7.
6. Devesa I, Ferrandiz ML, Terencio MC, Joosten LA, van den Berg WB, Alcaraz MJ. Influence of heme oxygenase 1 modulation on the progression of murine collagen-induced arthritis. Arthritis Rheum 2005;52:3230-8.
7. Zwerina J, Tzima S, Hayer S, Redlich K, Hoffmann O, Hanslik-Schnabel B, Smolen JS, Kollias G, Schett G. Heme oxygenase 1 (HO-1) regulates osteoclastogenesis and bone resorption. FASEB J 2005;19:2011-3.
8. Ryter SW, Otterbein LE. Carbon monoxide in biology and medicine. Bioessays 2004;26:270-80.
9. Alberto R, Motterlini R. Chemistry and biological activities of CO-releasing molecules (CORMs) and transition metal complexes. Dalton Trans 2007;17:1651-60.
10. Bani-Hani MG, Greenstein D, Mann BE, Green CJ, Motterlini R. Modulation of thrombin-induced neuroinflammation in BV-2 microglia by carbon monoxide-releasing molecule 3. J Pharmacol Exp Ther 2006;318:1315- 22.
11. Sawle P, Foresti R, Mann BE, Johnson TR, Green CJ, Motterlini R. Carbon monoxide-releasing molecules (CO-RMs) attenuate the inflammatory response elicited by lipopolysaccharide in RAW264.7 murine macrophages. Br J Pharmacol 2005;145:800-10.
12. Urquhart P, Rosignoli G, Cooper D, Motterlini R, Perretti M. Carbon monoxide-releasing molecules modulate leukocyte-endothelial interactions under flow. J Pharmacol Exp Ther 2007;321:656-62.
13. Lubberts E, Joosten LA, van Den Bersselaar L, Helsen MM, Bakker AC, van Meurs JB, et al. Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction. J Immunol 1999;163:4546-56.
14. Lubberts E, Joosten LA, Chabaud M, van Den Bersselaar L, uppers B, Coenen-De Roo CJ, et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000;105:1697-710.
15. Lubberts E, Koenders MI, Oppers-Walgreen B, Van Den BL, Coenen-De Roo CJ, Joosten LA, van den Berg WB. Treatment with a neutralising anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004;50:650-9.
16. Mauri C, Williams RO, Walmsley M, Feldmann M. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol 1996;26:1511-8.
17. Szekanecz Z, Haines GK, Lin TR, Harlow LA, Goerdt S, Rayan G, Koch AE. Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) and the MS-1 antigen in normal and diseased human synovia. Their possible pathogenetic and clinical significance in rheumatoid arthritis. Arthritis Rheum 1994;37:221-31.
18. Joosten LA, Lubberts E, Durez P, Helsen MM, Jacobs MJ, Goldman M, van den Berg WB. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997;40:249-60.
19. Moroney MA, Alcaraz MJ, Forder RA, Carey F, Hoult JRS. Selectivity of neutrophil 5-lipoxygenase and cyclo-oxygenase inhibition by an anti-inflammatory flavonoid glycoside and related aglycone flavonoids. J Pharm Pharmacol 1988;40:787-92.
20. Luross JA, Williams NA. The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology 2001;103:407-16.
21. Pae HO, Oh GS, Choi BM, Chae SC, Kim YM, Chung KR, Chung HT. Carbon monoxide produced by heme oxygenase-1 suppresses T cell proliferation via inhibition of IL-2 production. J Immunol 2004;172:4744-51.
22. Lafaille JJ. The role of helper T cell subsets in autoimmune diseases. Cytokine Growth Factor Rev 1998;9:139-51.
23. Joosten LA, Lubberts E, Helsen MM, Saxne T, Coenen-De Roo CJ, Heinegard D, van den Berg WB. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Arthritis Res 1999;1:81-91.
24. Johansson AC, Hansson AS, Nandakumar KS, Backlund J, Holmdahl R. IL-10-deficient B10.Q mice develop more severe collagen-induced arthritis, but are protected from arthritis induced with anti-type II collagen antibodies. J Immunol 2001;167:3505-12.
25. Fernandez P, Guillen MI, Gomar F, Alcaraz MJ. Expression of heme oxygenase-1 and regulation by cytokines in human osteoarthritic chondrocytes. Biochem Pharmacol 2003;66:2049-52.
26. Ochi T, Ohkubo Y, Mutoh S. Role of cyclooxygenase-2, but not cyclooxygenase-1, on type II collagen-induced arthritis in DBA/1J mice. Biochem Pharmacol 2003;66:1055-60.
27. van den Berg WB, Joosten LA, Kollias G, van de Loo FA. Role of tumour necrosis factor α in experimental arthritis: separate activity of interleukin 1β in chronicity and cartilage destruction. Ann Rheum Dis 1999;58(Suppl 1):140-8.
28. Hom JT, Bendele AM, Carlson DG. In vivo administration with IL-1 accelerates the development of collagen-induced arthritis in mice. J Immunol 1988;141:834-41.
29. Joosten LA, Helsen MM, Saxne T, van de Loo FA, Heinegard D, van den Berg WB. IL-1 α β blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-α blockade only ameliorates joint inflammation. J Immunol 1999;163:5049-55.
30. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006;12:17-25.
31. Kobayashi H, Takeno M, Saito T, Takeda Y, Kirino Y, Noyori K, et al. Regulatory role of heme oxygenase 1 in inflammation of rheumatoid arthritis. Arthritis Rheum 2006;54:1132-42.